Tags : Neurodegenerative Genetic Disorders


Axovant Sciences Licenses Two Gene Therapy Programs from University of

Shots: Axovant acquires WW development and commercialization rights for AXO-AAV-GM1 and AXO-AAV-GM2 Program and will make payments to University of Massachusetts The focus of the agreement is to develop functional copies of HEXA, HEXB & GLB1 genes encoding the certain enzymes to treat Gm1 Gangliosidosis, Tay-Sachs and Sandhoff Diseases AXO-AAV-GM1 program is initiated for GLB1 gene using AAV vector for […]Read More